BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic by Seini Moimoi | May 29, 2025 | Portfolio News
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease by Seini Moimoi | May 20, 2025 | Portfolio News
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) by Seini Moimoi | May 20, 2025 | Portfolio News
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma by Seini Moimoi | May 19, 2025 | Portfolio News
Cohere Health Secures $90M Series C to Expand AI-Powered Platform Transforming Health Plan Clinical Decision-Making by Seini Moimoi | May 14, 2025 | Portfolio News
